Plamotamab is under clinical development by Xencor and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Plamotamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plamotamab overview

Plamotamab (XmAb-13676) is under development for the treatment of B cell malignancies such as Richter's transformation, follicular lymphoma, relapsed and refractory Chronic Lymphocytic Leukemia, Marginal Zone B-Cell Lymphoma and non B-cell chronic lymphocytic leukemia. It is administered intravenously. The drug candidate is a bi-specific monoclonal antibody that targets tumor antigen binding domain CD20 and cytotoxic T-cell CD3 binding domain. The drug candidate development is based on XmAb bi-specific antibody engineering technology.

It was also under development for the treatment of relapsed/refractory diffuse large B-cell lymphoma,  Waldenstrom macroglobulinemia, splenic marginal zone B-Cell Lymphoma, extranodal marginal zone B-Cell Lymphoma, mantle cell lymphoma and nodal marginal zone B-Cell Lymphoma.

Xencor overview

Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.

For a complete picture of Plamotamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.